Medexus Pharmaceuticals Inc.
MEDXF
$2.39
$0.104.15%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -9.23% | -0.63% | -2.87% | -4.18% | -5.34% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -9.23% | -0.63% | -2.87% | -4.18% | -5.34% |
| Cost of Revenue | -21.00% | -9.06% | -8.54% | -6.59% | -5.70% |
| Gross Profit | -0.66% | 5.52% | 1.32% | -2.40% | -5.09% |
| SG&A Expenses | 14.74% | 14.92% | 3.88% | -3.76% | -9.84% |
| Depreciation & Amortization | 56.91% | 53.77% | 42.01% | 23.63% | 5.94% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.10% | 6.71% | 0.74% | -3.85% | -8.19% |
| Operating Income | -74.14% | -53.26% | -31.25% | -6.77% | 17.57% |
| Income Before Tax | -100.78% | -72.99% | -86.19% | 1,258.49% | 465.71% |
| Income Tax Expenses | 166.22% | 103.59% | -2,270.00% | -352.19% | 94.48% |
| Earnings from Continuing Operations | -107.64% | -83.40% | -26.19% | 1,150.00% | -39.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -107.64% | -83.40% | -26.19% | 1,150.00% | -39.42% |
| EBIT | -74.14% | -53.26% | -31.25% | -6.77% | 17.57% |
| EBITDA | -35.67% | -19.18% | -7.29% | 3.32% | 14.33% |
| EPS Basic | -106.88% | -81.62% | -11.52% | 882.79% | -51.61% |
| Normalized Basic EPS | -94.81% | -84.93% | -12.44% | 144.47% | 1,136.04% |
| EPS Diluted | -107.02% | -81.80% | -12.08% | 761.81% | -44.79% |
| Normalized Diluted EPS | -94.77% | -84.78% | -14.35% | 141.46% | 1,112.50% |
| Average Basic Shares Outstanding | 28.99% | 21.70% | 18.78% | 15.67% | 15.74% |
| Average Diluted Shares Outstanding | 27.88% | 20.65% | 19.69% | 16.62% | 13.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |